Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apricus Biosciences has filed an application with the US Food and Drug Administration (FDA) seeking orphan drug designation for RayVa as a treatment for Raynaud's phenomenon in patients with systemic sclerosis.
Subscribe to our email newsletter
RayVa is designed to be applied as a cream to fingers or toes, delivering alprostadil directly to the area of need, in order to stimulate blood flow.
Apricus chairman, president and CEO Bassam Damaj said they are continually expanding the potential uses for NexACT and other active drugs such as alprostadil, while also attempting to bring new treatments to patients with unmet medical needs.
"Our orphan drug filing for RayVa is the second such orphan drug filing we have made in the last several years and represents another milestone for the company," Damaj said.